ストックスクリーナーアプリを入手
424.86
3.06%
12.63
アフターアワーズ：
424.86
前日終値:
$412.23
開ける：
$412.69
24時間の取引高:
427.31K
Relative Volume:
1.19
時価総額：
$9.43B
収益：
-
当期純損益:
$-518.67M
株価収益率:
-16.91
EPS:
-25.12
ネットキャッシュフロー:
$-438.32M
1週間 パフォーマンス:
+11.94%
1か月 パフォーマンス:
+42.38%
6か月 パフォーマンス:
+19.38%
1年 パフォーマンス:
+66.09%
1日の値動き範囲:
$412.19
$426.73
1週間の範囲:
$378.55
$426.73
52週間の値動き範囲:
$200.63
$426.73
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
名前
Madrigal Pharmaceuticals Inc
セクター
電話
404-380-9263
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
424.86 | 8.72B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-06-28 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-04-22 | 開始されました | BofA Securities | Underperform |
| 2024-03-15 | アップグレード | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-02-26 | ダウングレード | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 繰り返されました | Oppenheimer | Outperform |
| 2022-12-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-19 | 繰り返されました | Piper Sandler | Overweight |
| 2022-12-19 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-11-24 | 再開されました | Evercore ISI | Outperform |
| 2020-11-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-05 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-01-30 | 開始されました | Canaccord Genuity | Buy |
| 2020-01-09 | アップグレード | UBS | Neutral → Buy |
| 2019-11-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-06-10 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-12-12 | 開始されました | B. Riley FBR | Neutral |
| 2018-11-19 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 開始されました | Citigroup | Buy |
| 2018-08-06 | ダウングレード | Goldman | Buy → Neutral |
| 2018-06-28 | 開始されました | Raymond James | Mkt Perform |
すべてを表示
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Rezdiffra's EU Approval: A Strategic Inflection Point for Madrigal and the MASH Market - AInvest
Madrigal Regains Lead With Rezdiffra MASH Approval In EU - insights.citeline.com
Madrigal Pharmaceuticals Inc. Rebound Backed by Sentiment ShiftWeekly Trade Analysis & Expert Curated Trade Setup Alerts - newsyoung.net
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU - Yahoo Finance
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Madrigal gets EU nod for its MASH treatment (MDGL:NASDAQ) - Seeking Alpha
Madrigal wins EC approval for Rezdiffra in MASH - The Pharma Letter
Madrigal’s MASH treatment Rezdiffra receives EU approval By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN
Madrigal’s MASH treatment Rezdiffra receives EU approval - Investing.com
Madrigal Pharmaceuticals' Rezdiffra Becomes First Approved Treatment for MASH in the European Union - Quiver Quantitative
Madrigal Receives European Commission Approval for - GlobeNewswire
Madrigal Pharmaceuticals, Inc. Receives European Commission Approval for Rezdiffra for the Treatment of MASH with Moderate to Advanced Liver Fibrosis - MarketScreener
Insider Selling at Madrigal Pharmaceuticals: Signal or Noise in the NASH Therapeutics Sector? - AInvest
Madrigal Pharmaceuticals’ general counsel sells $479,626 in stock By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals’ general counsel sells $479,626 in stock - Investing.com
Madrigal Pharmaceuticals stock reaches all-time high at 378.0 USD - Investing.com
Madrigal Pharmaceuticals stock reaches all-time high at 378.0 USD By Investing.com - Investing.com UK
Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs amid Wegovy approval - Investing.com Canada
Madrigal Pharmaceuticals Faces Market Jitters Amid New Rival - TipRanks
Why Nova Nordisk (NVO) Stock Is Climbing Today - Yahoo Finance
Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH - Investing.com Canada
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 - MSN
Is Madrigal Pharmaceuticals Inc. stock a hidden gemMarket Growth Summary & Low Drawdown Trading Techniques - classian.co.kr
Will Madrigal Pharmaceuticals Inc. outperform the market in YEAR2025 Volume Leaders & Real-Time Market Sentiment Reports - sundaytimes.kr
Why Madrigal Pharmaceuticals Shares Are Dropping - TipRanks
Director’s Major Stock Sale at Madrigal Pharmaceuticals Raises Eyebrows - TipRanks
Paulson's Q2 2025 13F Filing: Perpetua Resources Corp and More - AInvest
Madrigal Pharmaceuticals director Bate sells $3.6M in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals director Bate sells $3.6M in stock - Investing.com India
Assessing Madrigal Pharmaceuticals' Long-Term Market Potential in the LDL-C Lowering Therapy Sector Amid Competitive Dynamics - AInvest
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan - MSN
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Canaccord Genuity?s 45th Annual Growth Conference, Aug-12-2025 10 - MarketScreener
Is Madrigal Pharmaceuticals Inc. stock trending bullishPortfolio Risk Report & Growth Oriented Trading Recommendations - sundaytimes.kr
Madrigal Pharmaceuticals director sells $16.6m in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals Director Buys and Sells Shares Amid Price Volatility. - AInvest
Madrigal Pharmaceuticals director sells $16.6m in stock - Investing.com
MADRIGAL PHARMACEUTICALS Executives Sell Over $80 Million in Company Stock - TradingView
Madrigal Pharmaceuticals director Taub sells $16.5 million in stock By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals director Taub sells $16.5 million in stock - Investing.com
Madrigal Pharmaceuticals to Present at Canaccord Genuity Growth Conference - MSN
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - simplywall.st
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
Piper Sandler reiterates Overweight rating on Madrigal stock amid strong launch - Investing.com Canada
MDGL: UBS Raises Price Target Amidst Steady Buy Ratings | MDGL S - GuruFocus
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $523 From $458, Maintains Buy Rating - MarketScreener
Jefferies raises Madrigal Pharmaceuticals stock price target to $502 on patent extension - Investing.com Canada
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Madrigal Pharmaceuticals Inc (MDGL) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
0.90%
大文字化:
|
ボリューム (24 時間):